However, the response to the treatment revealed that MOG antibody-associated cortical encephalitis was sensitive to glucocorticoids (Ogawa et al., 2017; Tian et al., 2021; Yao et al., 2022), which is consistent with the response to the treatment and clinical prognosis of MOGAD (Ambrosius et al., 2020), but markedly different from anti NMDAR encephalitis. Here, MOG is linked to encephalitis.